BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34255389)

  • 1. Paraganglioma and other tumour detection rates in individuals with SDHx pathogenic variants by age of diagnosis and after the age of 50.
    Greenberg SE; Holman R; Kohlmann W; Buchmann L; Naumer A
    Clin Endocrinol (Oxf); 2021 Sep; 95(3):447-452. PubMed ID: 34255389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma-pheochromocytoma syndrome.
    Greenberg SE; Jacobs MF; Wachtel H; Anson A; Buchmann L; Cohen DL; Bonanni M; Bennett B; Naumer A; Schaefer AM; Kohlmann W; Nathanson KL; Else T; Fishbein L
    Genet Med; 2020 Dec; 22(12):2101-2107. PubMed ID: 32741965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
    Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice.
    Saie C; Buffet A; Abeillon J; Drui D; Leboulleux S; Bertherat J; Zenaty D; Storey C; Borson-Chazot F; Burnichon N; Vincent M; Favier J; Baudin E; Giraud S; Gimenez-Roqueplo AP; Amar L; Lussey-Lepoutre C
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1301-e1315. PubMed ID: 33247927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
    Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
    Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
    Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
    Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions.
    Gabriel S; Blanchet EM; Sebag F; Chen CC; Fakhry N; Deveze A; Barlier A; Morange I; Pacak K; Taïeb D
    Clin Endocrinol (Oxf); 2013 Aug; 79(2):170-7. PubMed ID: 23230826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.
    Xekouki P; Szarek E; Bullova P; Giubellino A; Quezado M; Mastroyannis SA; Mastorakos P; Wassif CA; Raygada M; Rentia N; Dye L; Cougnoux A; Koziol D; Sierra Mde L; Lyssikatos C; Belyavskaya E; Malchoff C; Moline J; Eng C; Maher LJ; Pacak K; Lodish M; Stratakis CA
    J Clin Endocrinol Metab; 2015 May; 100(5):E710-9. PubMed ID: 25695889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma.
    Timmers HJ; Gimenez-Roqueplo AP; Mannelli M; Pacak K
    Endocr Relat Cancer; 2009 Jun; 16(2):391-400. PubMed ID: 19190077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A need to tailor surveillance based on family history: describing a highly penetrant familial paraganglioma kindred with an SDHD pathogenic variant.
    Foley M; Sharma A; Garfield K; Maese L; Buchmann L; Boyle J; Kohlmann W; Jeter J; Greenberg S
    Fam Cancer; 2023 Apr; 22(2):217-224. PubMed ID: 36223042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
    Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid-sequence MRI for long-term surveillance for paraganglioma and phaeochromocytoma in patients with succinate dehydrogenase mutations.
    Daniel E; Jones R; Bull M; Newell-Price J
    Eur J Endocrinol; 2016 Dec; 175(6):561-570. PubMed ID: 27634942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES.
    Michałowska I; Ćwikła JB; Michalski W; Wyrwicz LS; Prejbisz A; Szperl M; Nieć D; Neumann HP; Januszewicz A; Pęczkowska M
    Endocr Pract; 2017 Mar; 23(3):342-352. PubMed ID: 27967220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators.
    Gimenez-Roqueplo AP; Caumont-Prim A; Houzard C; Hignette C; Hernigou A; Halimi P; Niccoli P; Leboulleux S; Amar L; Borson-Chazot F; Cardot-Bauters C; Delemer B; Chabolle F; Coupier I; Libé R; Peitzsch M; Peyrard S; Tenenbaum F; Plouin PF; Chatellier G; Rohmer V
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E162-73. PubMed ID: 23162105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic testing for pheochromocytoma and paraganglioma: SDHx carriers' experiences.
    Martins RG; Carvalho IP
    J Genet Couns; 2021 Jun; 30(3):872-884. PubMed ID: 33604970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germinal defects of SDHx genes in patients with isolated pituitary adenoma.
    Mougel G; Lagarde A; Albarel F; Essamet W; Luigi P; Mouly C; Vialon M; Cuny T; Castinetti F; Saveanu A; Brue T; Barlier A; Romanet P
    Eur J Endocrinol; 2020 Oct; 183(4):369-379. PubMed ID: 32621582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
    Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
    Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of
    Jha A; Ling A; Millo C; Gupta G; Viana B; Lin FI; Herscovitch P; Adams KT; Taïeb D; Metwalli AR; Linehan WM; Brofferio A; Stratakis CA; Kebebew E; Lodish M; Civelek AC; Pacak K
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):787-797. PubMed ID: 29204718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.